Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06434337 · ClinicalTrials.gov registry record
Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)
A clinical trial of Human Papilloma Virus, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT06434337: Recruiting study of Human Papilloma Virus, sponsored by M.D. Anderson Cancer Center.
NCT06434337 is a study of Human Papilloma Virus that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 600 participants, below the 8,426-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06434337, a study of Human Papilloma Virus, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if new HPV tests can provide the same results as standard HPV tests. The findings from this study may aid in the development of new HPV tests that require less equipment and are more accessible.
Primary Outcome
To evaluate the performance of the 3 version of a novel point-of-care diagnostic test for detecting HPV ("Rice HPV test").
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Novel point-of-care diagnostic test for detecting HPV ("Rice HPV test")
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2024-07-23 |
| Est. Completion | 2028-03-31 |
What NCT06434337 shows while recruiting
NCT06434337 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 8,426-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Human Papilloma Virus appearing as the primary indexed condition, and to 1 intervention - of which Novel point-of-care diagnostic test for detecting HPV ("Rice HPV test") is the first listed.
NCT06434337 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06434337 about?
NCT06434337 is a clinical study titled "Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)". To learn if new HPV tests can provide the same results as standard HPV tests. The findings from this study may aid in the development of new HPV tests that require less equipment and are more accessible.
What is the current status of trial NCT06434337?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2024-07-23. Estimated completion is 2028-03-31.
What conditions does trial NCT06434337 study?
This clinical trial studies the following conditions: Human Papilloma Virus.
What interventions are being tested in trial NCT06434337?
The interventions under investigation include: Novel point-of-care diagnostic test for detecting HPV ("Rice HPV test") (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06434337?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06434337 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06434337's enrollment target sits among peer trials
600 14th of 39 higher than 26 of 39 other Human Papilloma Virus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Papilloma Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
RECRUITING · NA
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma
RECRUITING
-
Merck IIT: RRP Pembro and Lenvatinib
RECRUITING · Early Phase 1
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI